Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Labrys Biologics begins operations with $31mm Series A financing, migraine antibody from Pfizer

Executive Summary

Lead investor venBio has teamed with Canaan Partners, InterWest Partners, Sofinnova Ventures, and one other undisclosed backer in the $31mm Series A financing for Labrys Biologics Inc., which has concurrently licensed from Pfizer the Phase I antibody RN307. Labrys will advance the candidate, which targets the calcitonin gene-related peptide (CGRP), into Phase II for chronic migraine later this year. VenBio's managing director Corey Goodman, PhD (also a former Pfizer exec), is Labrys' founder. Representatives from Canaan Partners, InterWest, and Sofinnova have joined the start-up’s board.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies